Financial Ratios

ALKEM LABORATORIES LTD.

NSE : ALKEMBSE : 539523ISIN CODE : INE540L01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE4711.9011.35 (+0.24 %)
PREV CLOSE ( ) 4700.55
OPEN PRICE ( ) 4703.15
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 677
TODAY'S LOW / HIGH ( )4695.65 4757.40
52 WK LOW / HIGH ( )3211.05 5519.1
NSE4720.9516.55 (+0.35 %)
PREV CLOSE( ) 4704.40
OPEN PRICE ( ) 4709.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 4720.95 (3527)
VOLUME 55269
TODAY'S LOW / HIGH( ) 4691.00 4759.65
52 WK LOW / HIGH ( )3186.3 5520
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)94.90128.92140.95105.7766.90
   CEPS(Rs)114.12147.24157.59121.3978.70
   DPS(Rs)50.0034.0030.0025.0016.00
   Book NAV/Share(Rs)782.09731.38637.87525.34457.15
   Tax Rate(%)14.5112.1010.575.5015.27
Margin Ratios
   Core EBITDA Margin(%)14.4719.4925.6321.0117.54
   EBIT Margin(%)14.8519.2825.3519.7116.31
   Pre Tax Margin(%)13.9418.8724.7819.1615.83
   PAT Margin (%)11.9216.5922.1618.1013.41
   Cash Profit Margin (%)14.3418.9524.7820.7815.78
Performance Ratios
   ROA(%)9.5514.0518.6116.9212.41
   ROE(%)12.5418.8324.2321.5315.45
   ROCE(%)13.1717.9623.4320.4617.05
   Asset Turnover(x)0.800.850.840.930.93
   Sales/Fixed Asset(x)3.313.523.163.233.23
   Working Capital/Sales(x)2.553.402.804.284.28
Efficiency Ratios
   Fixed Capital/Sales(x)0.300.280.320.310.31
   Receivable days67.8265.3174.6965.8956.37
   Inventory Days70.9668.5462.5554.4561.69
   Payable days118.55124.97139.56128.24144.19
Valuation Parameters
   PER(x)35.8128.0619.6722.0226.18
   PCE(x)29.7724.5717.5919.1822.26
   Price/Book(x)4.344.954.354.433.83
   Yield(%)1.470.941.081.070.91
   EV/Net Sales(x)4.374.894.544.243.68
   EV/Core EBITDA(x)24.0921.4915.3418.0918.91
   EV/EBIT(x)28.0124.1117.0220.5421.65
   EV/CE(x)3.403.563.343.413.16
   M Cap / Sales4.494.904.594.173.67
Growth Ratio
   Net Sales Growth(%)2.5522.308.1316.858.20
   Core EBITDA Growth(%)-18.26-6.0236.7940.453.63
   EBIT Growth(%)-21.10-7.0539.9841.610.58
   PAT Growth(%)-26.39-8.5433.2758.0811.73
   EPS Growth(%)-26.39-8.5433.2758.0811.73
Financial Stability Ratios
   Total Debt/Equity(x)0.120.260.170.190.09
   Current Ratio(x)2.221.661.931.631.83
   Quick Ratio(x)1.661.181.411.211.24
   Interest Cover(x)16.3647.2644.8935.5734.40
   Total Debt/Mcap(x)0.030.050.040.040.02

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.